NC-6100 / NANO MRNA - LARVOL DELTA

The 28th Japanese Society for Molecular Therapeutic Targets: Clinical Results of the Treatment of PRDM14 (siRNA) [Google translation] (Nikkei) - P1 | N=12 | jRCT2031190181 | Sponsor: NanoCarrier Co., Ltd. | "The 28th meeting of the Japan Association for Molecular Targeted Therapy will be held from June 19 to 21, 2024. The PRDM14 siRNA of the Japan Association for Molecular Targeted Therapy will be held on June 19th to 21st...10 patients with HER2-negative metastatic breast cancer were treated with PRDM14 siRNA/YBC...complex administration and side effects were confirmed, and the safety was confirmed and the problem was solved; The anti-tumor effect was 6PD, 4SD in 10 cases, the highest dose was 1 case in the SD stage, and the survival period without improvement was 25-180 days (central limit 45 days); Regarding pharmacokinetics, it was confirmed that PRDM14 siRNA exposure increased with increasing dose of PRDM14 siRNA/YBC polymer complex administration, and at the highest dose, the effective plasma concentration extrapolated from non-clinical results was reached."

P1 data • PK/PD data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor